RISE for Nurse Preceptors

October 21, 2025 updated by: AdventHealth

A Randomized Controlled Trial of RISE for Nurse Preceptors

The purpose of this study is to determine whether RISE for Nurse Preceptors has a significant impact on nurse preceptors' burnout, resilience, insight, self-compassion, and empowerment, as well as mental well-being, in their personal lives and their working environment.

Study Overview

Study Type

Interventional

Enrollment (Estimated)

124

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Florida
      • Orlando, Florida, United States, 32804
        • AdventHealth

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

  1. Adult ≥ 18 years old
  2. Licensed as an RN
  3. Employed by AdventHealth Rocky Mountain Region
  4. Completion of the AdventHealth preceptor training
  5. Has precepted ≥ 48 hours within the past calendar year in an AdventHealth hospital setting or outpatient emergency center
  6. Able to speak, read, and understand English fluently
  7. Able to provide informed consent
  8. Willing and able to comply with all study procedures and requirements for the duration of the study.

Exclusion Criteria:

  1. Has precepted < 48 hours within the past calendar year
  2. Does not pass the brief risk assessment in the pre-intervention introduction meeting with the LMHC facilitator
  3. Unwilling or unable to comply with all study procedures and requirements for the duration of the study.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Supportive Care
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Intervention group
Intervention group will attend the RISE for Nurse Preceptors program, which consists of nine 90-minute weekly psychoeducational group sessions facilitated by a licensed mental health counselor (LMHC)
Psychoeducational group program designed to impact resilience, insight, self-compassion, and empowerment
Active Comparator: Wait-list control group
Control group will attend the RISE for Nurse Preceptors program after the 6-month wait-list period
Psychoeducational group program designed to impact resilience, insight, self-compassion, and empowerment

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Professional Quality of Life Scale
Time Frame: Baseline, endpoint, and 1-, 3-, and 6-month follow-up
30-item questionnaire with the following response categories: 1=never, 2=rarely, 3=sometimes, 4=often, 5=very often
Baseline, endpoint, and 1-, 3-, and 6-month follow-up

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Posttraumatic Growth Inventory
Time Frame: Baseline, endpoint, and 1-, 3-, and 6-month follow-up
21-item questionnaire with a scale of 0-5, with 0 meaning I did not experience this change as a result of my crisis; and 5 meaning I experienced this change to a very great degree as a result of my crisis
Baseline, endpoint, and 1-, 3-, and 6-month follow-up
Brief Resilience Scale
Time Frame: Baseline, endpoint, and 1-, 3-, and 6-month follow-up
6-item questionnaire with the following response categories: 1=strongly agree, 2=disagree, 3=neutral, 4=agree, 5=strongly agree
Baseline, endpoint, and 1-, 3-, and 6-month follow-up
Self-Reflection and Insight Scale
Time Frame: Baseline, endpoint, and 1-, 3-, and 6-month follow-up
20-item questionnaire with a scale of 1-6; with 1 meaning strongly disagree; and 6 meaning strongly agree
Baseline, endpoint, and 1-, 3-, and 6-month follow-up
Self-Compassion Scale - Short Form
Time Frame: Baseline, endpoint, and 1-, 3-, and 6-month follow-up
12-item questionnaire with the following response categories: 1=almost never, 2, 3, 4, 5=almost always
Baseline, endpoint, and 1-, 3-, and 6-month follow-up
Psychological Empowerment Instrument
Time Frame: Baseline, endpoint, and 1-, 3-, and 6-month follow-up
12-item questionnaire with a scale of A-G, with A meaning very strongly disagree; and G meaning very strongly agree
Baseline, endpoint, and 1-, 3-, and 6-month follow-up
General Self-Efficacy Scale
Time Frame: Baseline, endpoint, and 1-, 3-, and 6-month follow-up
10-item questionnaire with the following response categories: 1=not at all true, 2=barely true, 3=moderately true, 4=exactly true
Baseline, endpoint, and 1-, 3-, and 6-month follow-up
Perceived Stress Scale
Time Frame: Baseline, endpoint, and 1-, 3-, and 6-month follow-up
10-item questionnaire with the following response categories: 0=never, 1=almost never, 2=sometimes, 3=fairly often, 4=very often
Baseline, endpoint, and 1-, 3-, and 6-month follow-up
Moral Injury Outcomes Scale
Time Frame: Baseline, endpoint, and 1-, 3-, and 6-month follow-up
14-item questionnaire with the following response categories: 0=strongly agree, 1=disagree, 2=neither agree or disagree, 3=agree, 4=strongly agree
Baseline, endpoint, and 1-, 3-, and 6-month follow-up
Brief COPE
Time Frame: Baseline, endpoint, and 1-, 3-, and 6-month follow-up
28-item questionnaire with a scale of 1-4, with 1 meaning I haven't been doing this at all; and 4 meaning I've been doing this a lot
Baseline, endpoint, and 1-, 3-, and 6-month follow-up
Generalized Anxiety Disorder - 2 item scale
Time Frame: Baseline, endpoint, and 1-, 3-, and 6-month follow-up
2-item questionnaire with the following response categories: 0=not at all, 1=several days, 2=more than half the days, 3=nearly every day
Baseline, endpoint, and 1-, 3-, and 6-month follow-up
Patient Health Questionnaire - 2 item
Time Frame: Baseline, endpoint, and 1-, 3-, and 6-month follow-up
2-item scale with the following response categories: 0=not at all, 1=several days, 2=more than half the days, 3=nearly every day
Baseline, endpoint, and 1-, 3-, and 6-month follow-up
Preceptor Self-Assessment Tool
Time Frame: Baseline, endpoint, and 1-, 3-, and 6-month follow-up
40-item scale with the following response categories: 1 (lowest), 2 (low), 3 (average), 4 (high), 5 (highest).
Baseline, endpoint, and 1-, 3-, and 6-month follow-up

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Investigators

  • Principal Investigator: Amanda T Sawyer, PhD, AdventHealth

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

March 1, 2025

Primary Completion (Estimated)

February 28, 2026

Study Completion (Estimated)

February 28, 2026

Study Registration Dates

First Submitted

February 7, 2025

First Submitted That Met QC Criteria

February 11, 2025

First Posted (Actual)

February 12, 2025

Study Record Updates

Last Update Posted (Estimated)

October 22, 2025

Last Update Submitted That Met QC Criteria

October 21, 2025

Last Verified

July 1, 2025

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe